Patients wake up from surgery, stabilize, and then suffer a second stroke
In the fragile window between surviving a brain hemorrhage and the body's own inflammatory response turning against itself, medicine has long stood nearly helpless. This week, the FDA granted breakthrough device designation to Aurenar's V-Link — a small nerve-stimulating device worn behind the ear — which in an early trial reduced the most dangerous form of post-hemorrhage vessel constriction by more than forty percent. The designation does not confirm the device works at scale, but it signals that the question is worth asking urgently, and that the path to an answer will be cleared of ordinary delays. For patients who wake from surgery only to face a second, silent injury days later, the promise of prevention — rather than rescue — represents a meaningful shift in what care might look like.
- Cerebral vasospasm — the constriction of brain vessels days after a hemorrhage — has long been medicine's cruel second blow, striking patients who survived the initial bleed and leaving doctors with almost no way to stop it before it begins.
- Aurenar's V-Link challenges that helplessness directly, using gentle electrical pulses to the vagus nerve to quiet the inflammatory cascade before vessels narrow — a preventive strategy where only reactive ones existed before.
- A small but rigorously blinded trial of twenty-seven patients showed a forty-percent reduction in moderate-to-severe vasospasm with no safety concerns, results striking enough to earn the FDA's breakthrough designation and accelerate the path to larger testing.
- The device is designed to slip into ICU routines with minimal disruption — twenty minutes twice a day, minimal staff training required — lowering the barrier between a promising result and real-world adoption.
- Larger pivotal trials now stand between the V-Link and standard care, and the company is moving forward with deliberate caution, aware that what holds in twenty-seven patients must still prove itself across hundreds.
A device small enough to wear behind the ear may be the first tool capable of preventing one of neurology's most devastating secondary injuries. The FDA this week granted breakthrough designation to the V-Link, made by Aurenar, a device that delivers gentle electrical pulses to the vagus nerve to interrupt the inflammatory cascade that causes cerebral vasospasm — the dangerous constriction of brain vessels that strikes days after a hemorrhage, long after the initial crisis appears to have passed.
For decades, the medical response to vasospasm has been largely reactive. An oral medication offers modest protection; when vessels narrow anyway, doctors may attempt invasive procedures to physically reopen them. But the inflammation driving the constriction begins immediately after the bleed, and by the time symptoms appear, the damage is already unfolding. Aurenar's approach is to intervene before that window closes — calming the body's response early, during the ICU stay, through twice-daily twenty-minute sessions with a device designed to integrate into existing care routines without demanding significant retraining.
In a twenty-seven-patient randomized, triple-blinded trial, the device reduced moderate-to-severe vasospasm by more than forty percent, with no safety concerns emerging. The rigor of the study design — patients, clinicians, and outcome assessors all unaware of who received the real device — lends weight to results that might otherwise be dismissed at this scale. CEO Eric Leuthardt has been candid about the limitation: twenty-seven patients is a beginning, not a conclusion.
The breakthrough designation is designed precisely for moments like this — to clear regulatory pathways so that larger pivotal trials can proceed with urgency. If those trials confirm what the early data suggests, the V-Link could become standard ICU care within a few years. Aurenar also sees the same inflammation-modulating mechanism as a foundation for future applications in other high-acuity conditions, though the immediate focus remains on the patients who survive a brain bleed only to face the quiet threat of a second injury days later.
A device the size of an earbud, worn for twenty minutes twice a day, may have just changed what happens to thousands of people in the days after their brains bleed.
This week the FDA granted breakthrough device designation to the V-Link, made by a company called Aurenar. The device delivers gentle electrical pulses to a nerve behind the ear—the vagus nerve—with the goal of stopping a cascade of injury that kills or cripples many patients who survive the initial hemorrhage. That cascade is called cerebral vasospasm. It happens when blood vessels in the brain constrict in the days following an aneurysm, strangling blood flow to brain tissue. Patients wake up from surgery, stabilize, and then suffer what amounts to a second stroke, this one triggered not by bleeding but by the body's own inflammatory response gone haywire.
For decades, medicine has had almost no way to stop it. Doctors can give an oral medication. If that fails, they can try invasive rescue procedures like balloon angioplasty—threading a catheter into the brain to physically widen the vessels again. But prevention has been out of reach. The inflammation that drives vasospasm begins immediately after the bleed, before anyone can intervene. By the time the vessels start to narrow, days later, the damage is already in motion.
Aurenar's approach is to get ahead of it. The V-Link works on the theory that if you can calm the body's inflammatory response early—before the vessels constrict—you might prevent vasospasm altogether. The device sends electrical signals through the vagus nerve, which acts as a kind of master switch for inflammation. Patients wear it during their ICU stay, twenty minutes in the morning and twenty minutes in the evening, while nurses and doctors manage their other care. The company designed it to fit into existing workflows with minimal training required.
In a small trial of twenty-seven patients, the approach worked. The device cut moderate-to-severe vasospasm by more than forty percent. No safety problems emerged. The trial was randomized and triple-blinded—patients, clinicians, and the people measuring outcomes all didn't know who got the real device and who got a placebo—which is the gold standard for a study this size. The effect was substantial and statistically significant, and it aligned with what researchers would expect from vagus nerve stimulation based on what we know about how the nerve controls inflammation.
Eric Leuthardt, Aurenar's CEO, acknowledged the obvious limitation: twenty-seven patients is not a lot. The breakthrough designation exists precisely to speed the path toward larger pivotal trials that will test whether the benefit holds up when the device is used in hundreds or thousands of patients across many hospitals. Leuthardt said the company is approaching the next phase with appropriate caution. The goal is to confirm that what worked in the small trial works in the real world.
Beyond vasospasm, Aurenar sees the same mechanism—using electrical stimulation to modulate inflammation—as potentially useful in other high-acuity ICU conditions. The company's immediate focus is on the brain hemorrhage indication, but the long-term vision is to expand one indication at a time, testing the device in other settings where runaway inflammation causes harm. For now, the next step is the larger trial. If that succeeds, the V-Link could become standard care in ICUs within a few years, changing the trajectory for thousands of patients each year who survive a brain bleed only to face the risk of a second injury days later.
Notable Quotes
The 27-patient trial was randomized, triple-blinded, which is the strongest study design for a trial of this size. The effect size we saw was substantial and reached statistical significance.— Eric Leuthardt, Aurenar CEO
Aurenar is approaching its evidence generation with the appropriate humility. The breakthrough designation is meant to speed up the path toward larger pivotal trials.— Eric Leuthardt, Aurenar CEO
The Hearth Conversation Another angle on the story
Why does vasospasm happen at all? Why does the body do this to itself after a hemorrhage?
It's the inflammatory response. When blood spills into the brain, the body treats it as a threat and launches an immune cascade. That cascade is meant to clean up and heal, but it goes too far—the inflammation itself causes the blood vessels to constrict. It's a protective mechanism that backfires.
And the vagus nerve is the off switch?
Not exactly an off switch, but a dimmer. The vagus nerve has branches that reach into the organs and can suppress inflammatory signals. Stimulating it tells the body to dial down the immune response before it damages the vessels.
Why hasn't anyone tried this before?
They have, in other contexts. Vagus nerve stimulation is used for epilepsy and depression. But applying it specifically to prevent vasospasm after brain hemorrhage—that's new. It required understanding the mechanism, designing a device that fits ICU workflows, and then proving it works in this specific population.
Twenty-seven patients feels small.
It is. But the trial was designed perfectly—randomized, triple-blinded. The effect size was large enough to reach statistical significance despite the small number. That's why the FDA took notice. It's not proof, though. The pivotal trials will involve hundreds of patients across many hospitals. That's where you find out if it really works in the messy real world.
What happens if the larger trials fail?
Then you learn something important about the mechanism or the patient population. But Leuthardt seems confident because the biology makes sense. The inflammation-modulation pathway is well-understood. The question is just whether it's strong enough to prevent vasospasm at scale.